Patient‐reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy
Kelley M. Kidwell(University of Michigan), N. Lynn Henry(University of Michigan), David A. Williams(Rockefeller University), Janet S. Carpenter(Indiana University – Purdue University Indianapolis), Anna Maria Storniolo(Indiana University Health), Vered Stearns(Johns Hopkins University), Daniel F. Hayes(University of Michigan–Ann Arbor), Daniel J. Clauw(University of Michigan), David A. Flockhart(Indiana University – Purdue University Indianapolis), Steven E. Harte(University of Michigan)
Cited by 98
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
The American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and Measurement of Symptom Severity
|Arthritis Care & Research|2010|3.9k